To read the full story, subscribe or sign in.

Zai Lab to develop Turning Point drug for NSCLC in China

July 14, 2020

HONG KONG – Zai Lab Ltd. inked a deal to develop and commercialize Turning Point Therapeutics Inc.’s lead drug candidate, repotrectinib, in the greater China markets.

BioWorld Asia Deals and M&A Cancer China

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2025.

Medline raises $6.3B in fourth med-tech IPO of December

BioWorld MedTech

Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 17, 2025.

Vitesse finesse pays off: DBV wins in peanut allergy phase III

BioWorld

DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....

Acryl raises $28M IPO, aiming to bridge medical divide with AI

BioWorld MedTech

Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...